Upstream Bio Inc
Research Upstream Bio Inc (UPB) on Bullrun: market cap USD 393.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUPB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 393.26M
- Financial periodQ1 2026
- RevenueUSD 1.03M
- Net income-USD 40.59M
- Free cash flow-USD 47.85M
Valuation Snapshot
latest market cap is USD 393.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.85M | -USD 143.44M | -USD 133.44M | n/a | -2.66 | USD 101.58M | USD 1.27M | USD 339.77M |
| FY2024 | USD 2.37M | -USD 62.81M | -USD 59.68M | n/a | -5.58 | USD 325.89M | USD 1.83M | USD 469.85M |
| FY2023 | USD 2.38M | -USD 20.54M | -USD 38.07M | n/a | -12.95 | USD 25.83M | USD 45.00K | -USD 123.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 393.26M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.47B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 881.24M | n/a | n/a | n/a |
About Upstream Bio Inc
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Upstream Bio Inc's market cap?
Upstream Bio Inc's market capitalization is USD 393.26M.
What does Upstream Bio Inc do?
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.